Patent Application
20250195578
The present disclosure relates to a culture medium for culturing urine-derived stem cells and specifically to a culture medium for enhancing the expression of klotho in urine-derived stem cells. Also, the present disclosure relates to a method for isolating and culturing urine-derived stem cells with improved therapeutic functions for kidney disease.
Currently used chronic kidney disease treatments cannot restore damaged kidney tissue, so chronic kidney disease eventually develops into end-stage renal failure. Despite advancements in treatment, the mortality rate remains high (M J Lee., 2020).
Many efforts have been made to find new treatments to restore the kidney damage, and stem cell therapy has been proposed. Among them, mesenchymal stem cells are recognized for their potential as a new treatment for chronic kidney disease due to their therapeutic efficacy in inflammation and immune response regulation, and angiogenesis. Currently, bone marrow and fat are useful as representative sources of mesenchymal stem cells that can be obtained and differentiated from adults, but since the collection process is invasive, it can cause damage to surrounding tissues. In addition, the low cell yield and purity remain problems to be addressed in applying these cells as a therapy. Therefore, it is necessary to develop a new cell source that can be easily cultured in vitro without causing excessive pain and damage to the patient during the cell collection process and can maintain the characteristics of stem cells well even after long-term culture.
The stem cells of the present disclosure are urine-derived stem cells (UDSC) that can be separated through a simple separation process from human urine and which are derived from renal tubules, renal papillary cells, and epithelial cells of the glomerular wall and are created through the epithelial-mesenchymal transition (EMT) process. It is not yet fully understood how epithelial cells lose cell polarity and change into cells with therapeutic efficacy like mesenchymal stem cells, but it is known that these transformed pluripotent cells play an important role in kidney recovery and regeneration. These urine-derived stem cells can be obtained multiple times without causing any pain or sequelae to the patient, can provide a large number of cells in a short period of time due to their high proliferation rate, and have telomerase activity that is not well expressed in general mesenchymal stem cells, so they are known to have high resistance to cell aging (Qin et al., 2014).
Urine-derived stem cells have the characteristics of self-renewal and therapeutic potential to produce various cells that make up the kidney. In fact, in many studies, urine-derived stem cells can differentiate into various cells experimentally and are known to secrete various paracrine factors that promote angiogenesis. They have also been found to have immune regulatory functions by inhibiting the proliferation of peripheral blood mononuclear cells (PBMC), T cells, B cells, and secreting IL-6 and IL-8 (Qin et al., 2014).
Also, from a regenerative medicine perspective, organ-specific stem cells are generally known to be ideal for treating the organs from which they were separated or originated. For this reason, urine-derived stem cells can be the most suitable option for the treatment and regeneration of the urinary reproductive system and kidneys. Urine-derived stem cells can differentiate into smooth muscle, epithelial and endothelial cells, and podocytes that make up most of the kidney tissue, and these cells are known to lead to the development of kidney-like tissues that can function as kidneys (Qin et al., 2014).
On the other hand, Klotho is known as a representative anti-aging factor. Klotho is a protein discovered through research to extend the lifespan of mice and is known to be mainly expressed in the kidney or pituitary gland (Kuro-o M et al., 1997). Klotho mainly is secreted from the proximal and distal renal tubules in the body and functions like a hormone, is involved in insulin and IGF-1 cell signaling pathways, maintains endocrine homeostasis of calcium, phosphorus, potassium, etc., and is known to function in angiogenesis and antioxidation.
Under normal physiological conditions, the kidney performs an important role in maintaining klotho expression, but it has been revealed in several papers that when the kidney is damaged, the expression of klotho also decreases, and klotho is being studied as an early biomarker for kidney damage (Qi Wang et al., 2018). In addition, many studies have been conducted to observe the recovery from proteinuria and blood sugar and of glomerular filtration rate, etc. by administering recombinant klotho protein to animal models of kidney disease with the klotho gene removed, reporting that klotho is a potential therapeutic factor for chronic kidney damage (Neyra et al., 2017).
According to existing research, Klotho is known to activate recovery mechanisms by enhancing overall cellular metabolic function, such as restoring mitochondrial function in damaged kidneys, maintaining ion channel homeostasis, and enhancing the production of antioxidants. The associated mechanisms are known to involve various signaling pathways such as mTOR, NF-kB, AMPK, Wnt/β-catenin, Nrf-2, etc. (Marlena T et al., 2021).
As stated in the foregoing, klotho protein is being researched for the development of treatments for various chronic diseases including kidney damage. The methods of delivering klotho protein to patients are mainly mentioned as using small molecules or peptides and using genetic material such as nucleic acids, but the duration of effect and safety are limitations to be overcome. In this regard, the present research team has developed a technology to culture urine-derived stem cells with increased Klotho expression than the conventional culture technology of urine-derived stem cells, and confirmed the efficacy in animal models of kidney disease through the homing effect of urine-derived stem cells (the ability to move to the wound site when administered intravenously) and klotho expression and secretion.
In relation to this, Korean Patent No. 10-2021-0053725 A discloses a medium composition for culturing urine-derived stem cells and a method for culturing urine-derived stem cells using same. However, the document does not disclose at all about a culture solution containing parathyroid hormone (PTH) as an additive.
Through the previous research into characteristics of urine-derived stem cells, the present inventors discovered that urine-derived stem cells retain the therapeutic characteristics of typical mesenchymal stem cells and also express Klotho, a therapeutic factor for kidney disease. This suggests that urine-derived stem cells can be used as a therapeutic agent with higher therapeutic efficacy in kidney-related diseases compared to other stem cells that do not typically express klotho. Many studies have recently been conducted to use klotho as a therapeutic agent in various kidney diseases including chronic kidney disease. From this perspective, urine-derived stem cells, which are stem cells that can naturally secrete klotho, can be an alternative to relatively safe methods for klotho application to humans that do not require special delivery technology. In addition, it was noted that they can be developed into excellent cell therapeutics for kidney disease because of secretion of various therapeutic factors of stem cells.
Leading to the present disclosure, thorough and intensive research conducted by the present inventors resulted in devising a method that can excellently the rate stem cell maintain proliferation and characteristics of urine-derived stem cells even in long-term in vitro culture and can excellently enhance Klotho expression.
An aspect of the present disclosure is to provide a culture medium and a method for isolating and culturing urine-derived stem cells using same, wherein the culture medium is able to excellently maintain the proliferation rate and stem cell characteristics of urine-derived stem cells even in long-term in vitro culture and enhance Klotho expression.
Another aspect of the present disclosure is to provide a method for producing urine-derived stem cells with enhanced kidney disease treatment function through increased klotho expression.
A further aspect of the present disclosure is to provide a cell therapy product that includes, as an active ingredient, urine-derived stem cells with enhanced kidney disease treatment function through increased Klotho expression.
A first embodiment of the present disclosure provides a culture medium for the isolation and culture of urine-derived stem cells, wherein the culture medium includes a basic medium containing Dulbecco's Modified Eagle Medium (DMEM) and Ham's F-12, 5% or less fetal bovine serum, and parathyroid hormone (PTH) and may additionally include one or more additives selected from the group consisting of bovine serum albumin, triiodothyronine (T3), and bovine serum albumin.
The basic medium is preferably prepared by mixing of Dulbecco's Modified Eagle Medium (DMEM) and Ham's F-12 at a volume ratio of 1:1 to 5:1, and more preferably at a volume ratio of 2:1 to 3:1.
The fetal bovine serum is preferably added at 0.1% by volume to 10% by volume and more preferably at 2.5% by volume to 5% by volume, based on the total volume of the medium.
The bovine serum albumin is preferably contained at a concentration of 0.1 mg/mL to 10 mg/mL based on the total volume of the medium, and more preferably at a concentration of 2.5 mg/mL to 5 mg/mL.
The chemically defined lipids are preferably contained at a concentration of 0.1% by volume to 10% by volume based on the total volume of the medium, and more preferably at a concentration of 1% by volume to 5% by volume.
The FGF23 is preferably included at a concentration of 0.1 ng/mL to 200 ng/ml based on the total volume of the medium, and more preferably at a concentration of 10 ng/ml to 100 ng/mL.
The T3 may be preferably contained in concentration of 0.1 nM to 40 nM, based on the total culture medium, and more preferably in a concentration of 10 nM to 20 nM.
The calcifediol may be preferably contained in a concentration of 1 nM to 1000 nM, based on the total culture medium, and more preferably in a concentration of 100 nM to 500 nM.
The parathyroid hormone (PTH) may be preferably contained in a concentration of 1 nM to 2000 nM, based on the total culture medium, and more preferably in a concentration of 100 nM to 1000 nM.
A second embodiment of the present disclosure provides a method for isolating urine-derived stem cells, the method including the steps of:
A third embodiment of the present disclosure provides a method for culturing urine-derived stem cells, the method including a step of inoculating the urine-derived stem cells with the culture medium and culturing same.
The cultured urine-derived stem cells may have:
A fourth embodiment of the present disclosure provides urine-derived stem cells cultured in the culture medium.
The urine-derived stem cells may have an enhanced kidney disease treatment function.
The urine-derived stem cells may be positive for CD73, CD90, CD105, CD146, or SSEA-4.
The urine-derived stem cells may be autologous, allogeneic, or xenogeneic.
The urine-derived stem cells may decrease the neutrophil gelatinase-associated lipocalin (NGAL) level.
The kidney disease may be one or more selected from a group consisting of diabetic nephropathy, chronic renal failure, acute renal failure, subacute renal failure, glomerulonephritis, malignant nephrosclerosis, vascular microangiopathy, transplant rejection, glomerulopathy, kidney hypertrophy, kidney proliferation, proteinuria, contrast-induced nephropathy, toxin-induced kidney damage, oxygen free-radical-mediated kidney disease, and nephritis.
A fifth embodiment of the present disclosure provides a cell therapy product with enhanced kidney disease treatment function, wherein the cell therapy product includes urine-derived stem cells as an active ingredient.
The cell therapy product may be a preparation adapted to be administered via an oral, rectal, intravenous (i.v), intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, local, intraocular, subcutaneous, or intradermal route.
The cell therapy product may further include a pharmaceutical carrier.
The urine-derived stem cells according to the present disclosure showed effects of improving kidney function and regenerating tissues in a kidney disease animal model. Furthermore, urine-derived stem cells can be cultured at a mass scale and developed into stem cell therapeutics targeting diseases of the urinary system, with the expectation of a use as safe and efficient therapeutics for various intractable diseases.
The term “stem cells,” as used herein, refers to cells that have the potential to differentiate into cells of all tissues in an organism, possessing pluripotency or totipotency, and also exhibit self-renewal capability. The term is intended to encompass embryonic stem cells, induced pluripotent stem cells, and adult stem cells.
As used herein, the term “proliferation” of stem cells refers to the process where the stem cells divide, maintaining their stem cell characteristics without differentiating into specific cells, and thus increasing the total number of cells.
As used herein, the term “culture medium” refers to a composition that contains nutrients necessary for maintaining the growth and survival of cells in vitro.
As used herein, the term “passage culture” refers to a method of continuously culturing cells for a long period of time in a healthy state by periodically transferring a portion of the cells to a new culture vessel and exchanging the culture medium with a fresh one. As the number of cells increases in a culture vessel with limited space, the proliferative nutrients are consumed or contaminants accumulate over time, causing the cells to naturally die. Therefore, it is used as a means to increase the number of healthy cells. Typically, one passage means one round of replacing the culture medium (or culture vessel) once with a fresh one or dividing a population of cells into sub-groups.
As used herein, the term “subject” refers to a target that requires treatment for kidney disease, specifically including mammals such as humans or non-human primates, mice, dogs, cats, horses, and cows.
The term “cell therapy product”, as used herein, refers to cells and tissues that have been isolated, cultured, and prepared from a subject through special manipulation and are used as pharmaceuticals for the purpose of treatment, diagnosis, and prevention. It means a pharmaceutical for use in treating, diagnosing, and preventing diseases through a series of actions including proliferating and selecting living autologous cells, allogeneic cells, or xenogeneic cells in vitro or changing the biological characteristics of cells in other ways for the purpose of restoring the function of cells or tissues.
According to a first embodiment thereof, the present disclosure provides a culture medium for the isolation and culture of urine-derived stem cells, wherein the culture medium includes: a basic medium containing Dulbecco's Modified Eagle Medium (DMEM) and Ham's F-12; fetal bovine serum; and parathyroid hormone (PTH) and may further include one or more additives selected from the group consisting of calcifediol, bovine serum albumin, and chemically defined lipids.
According to a second embodiment thereof, the present disclosure provides a method for isolating urine-derived stem cells, the method including the steps of: (a) sampling urine from a subject; (b) centrifuging the urine to collect cells; (c) washing the cells, followed by centrifugation; and (d) inoculating the cells with the culture medium according to claim 1.
The method may additionally include a step of (e) harvesting urine-derived stem cells by treating the cells with trypsin.
In the method, the centrifugation may be performed at 300 g to 700 g for 5 to 15 minutes, but with no limitations thereto.
In the method, the washing may be performed by PBS (phosphate buffered saline), but with no limitations thereto.
According to a third embodiment thereof, the present disclosure provides a method for culturing urine-derived stem cells, the method including a step of inoculating the urine-derived stem cells with the culture medium and culturing same.
The method may further include step (h) of detaching the cultured urine-derived stem cells at a confluency of 70% to 90% by trypsinization, inoculating the cells at a density of 1×103 to 1×104 (cells/cm2) per area into a larger culture vessel, and then culturing the cells for 5 to 8 passages.
In the method, the washing may be performed by PBS (phosphate buffered saline), but with no limitations thereto.
According to a fourth embodiment thereof, the present disclosure provides urine-derived cells cultured in the culture medium.
According to a fifth embodiment thereof, the prevent disclosure provides a cell therapy product with enhanced kidney disease treatment function, wherein the cell therapy product includes urine-derived stem cells as an active ingredient.
In the cell therapy product, the urine-derived stem cells may be autologous, allogeneic, or xenogeneic.
In the cell therapy product, the kidney disease may be one or more selected from a group consisting of diabetic nephropathy, chronic renal failure, acute renal failure, subacute renal failure, glomerulonephritis, malignant nephrosclerosis, vascular microangiopathy, transplant rejection, glomerulopathy, kidney hypertrophy, kidney proliferation, proteinuria, contrast-induced nephropathy, toxin-induced kidney damage, oxygen free-radical-mediated kidney disease, and nephritis.
The cell therapy product may include additional pharmaceutical excipients commonly used in cell therapy. As used herein, the term “pharmaceutically acceptable” means physiologically acceptable so as not to cause allergic reactions or similar reactions such as gastrointestinal disorders, dizziness, and the like, upon administration to humans.
Examples of pharmaceutically acceptable excipients for parenteral administration include, but are not limited to, water, suitable oils, saline, aqueous glucose, and glycol. Stabilizers and preservatives may further be included. Suitable stabilizers may include antioxidants such as sodium bisulfite, sodium metabisulfite, or ascorbic acid. Suitable preservatives may include benzalkonium chloride, methyl- or propyl-parabens, and chlorobutanol. With respect to other pharmaceutically acceptable excipients, reference may be made to the literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
The cell therapy product may also be administered by means of any suitable device that guides the cell therapy product to target cells.
A better understanding of the present disclosure may be obtained through the following examples which are set forth to illustrate, but are not to be construed as limiting the present disclosure.
A total of 100 ml of urine was filtered through a 100 μm filter to remove particulate matter such as mucus. The filtered urine was divided into 50 ml tubes and centrifuged at 500×g 15 for minutes. After centrifugation, the supernatant was discarded, and the cell pellet was collected and washed with 1×PBS (Gibco). The washed cells were centrifuged at 500×g for 10 minutes. This washing process was repeated twice. Then, the supernatant was discarded, and the cell pellet was resuspended in a culture medium with the composition listed in Table 1. The resuspended cells were plated at a density of 500 μl per well into 24-well plates. The cells were cultured for 5 days at 37° C. under 5% CO2 in a humidified incubator to allow the formation of urine-derived stem cell colonies.
Since the plating, circular cell colonies consisting of tightly packed cells appeared in specific wells of the 24-well plates (
Immediately after isolation, the cells contained in the urine included renal tubular cells, uroepithelial cells, squamous epithelial cells, leukocytes, and erythrocytes. Among the cells derived from urine, 99% were non-adherent cells in the cell culture vessel and were removed during medium changes. Of the remaining cells, 0.1% was accounted for by cells derived from uroepithelial cells, muscle cells, and endothelial cells while 0.2% exhibited characteristics of urine-derived stem cells with multipotent differentiation capacity. In this non-urine-derived stem cells isolation method, were eliminated due to differences in proliferation rate compared to urine-derived stem cells. The urine-derived stem cell isolation and culture process are depicted in
For comparison and evaluation of cell proliferation rates, urine-derived stem cells were isolated and cultured using two types of media previously used in prior art (hereinafter, referred to as Media 1, Media 2), the culture medium according to Korean Patent No. 10-2021-0053725 A (hereinafter referred to as TM5-EXP), and the culture medium of the present disclosure (hereinafter referred to as TM8), as given in Table 3.
The cells were passaged every 4 days, and counted for each passage up to the 5th passage. The cell counts were measured using the ADAM cell counter (NanoEnTek, Korea). The cell proliferation rate was evaluated using the following formulas to calculate CPDL (Cumulative Population Doubling Level) and DT (Doubling Time):
As shown in
The analysis of doubling time (DT), which represents the time taken for cells to divide once, at the 5th passage revealed that Media 1 and Media 2 had DT values of 39.26 and 36.38 hours, respectively, while TM5-EXP and TM8 had DT values of 24.44 and 23.99 hours, respectively.
The analysis of cumulative population doubling level (CPDL), which represents the number of cell divisions up to the 5th passage, showed that Media 1 and Media 2 had CPDL values of 15.96 and 15.85, respectively, while TM5-EXP and TM8 had CPDL values of 20.13 and 20.39, respectively.
Based on the cell proliferation rate analysis, urine-derived stem cells cultured with TM5-EXP and TM8 exhibited relatively higher cell proliferation rates and maintained a high cell proliferation rate up to the 5th passage compared to those cultured with Media 1 and Media 2. However, there was no significant difference in the proliferation rate between TM5-EXP and TM8.
In this Example, urine-derived stem cells cultured with the culture media listed in Table 3 were compared and evaluated for their cell characteristics. The expression of specific surface markers on urine-derived stem cells was analyzed using flow cytometry at the 3rd and 5th passages of cell culture. It is known from previous studies that urine-derived stem cells possess at least one of the markers CD73, CD90, CD105, CD146, SSEA-4 and do not express at least one of CD31, CD34, and CD45. Therefore, analysis focus was imparted to these markers.
Specifically, urine-derived stem cells cultured with the culture media listed in Table 3 were collected at the 3rd and 5th passages, and 1×106 cells were resuspended in 500 μl of PBS (Gibco). The resuspended cells were distributed into FACS tubes (5 ml, poly styrene round-bottom, Falcon) at 100 μl per tube. FACS antibodies (Table 6) were added to each tube, and the tubes were incubated in the dark at room temperature for 20 minutes. After incubation, 500 μl of PBS was added to each tube, and the cells were analyzed using a flow cytometer. The FACSverse™ instrument from BD was used for cell analysis, following the instrument's measurement manual, and the analysis was performed using the analysis software.
The results are depicted in
The inventors speculated that these differences may be attributed to the various types and concentrations of additives such as extracts from the choroid plexus, growth factors, and hormones added to Media 1 and Media 2, which may have influenced the cell characteristics during long-term culture. On the other hand, the culture medium of the present disclosure included key growth factors and hormones that closely interact with human kidney cells, such as FGF23, Calcifediol, and PTH, while minimizing the addition of unnecessary growth factors and hormones. This may explain the observed differences in cell characteristics.
Therefore, in Example 4, the major gene expression levels of urine-derived stem cells in response to the addition of FGF23, Calcifediol, PTH, and other substances were examined using PCR analysis.
In this Example, real-time polymerase chain reaction (PCR) analysis was conducted to compare and evaluate the gene expression characteristics of urine-derived stem cells cultured with the culture media listed in Table 3 up to the 5th passage.
Urine-derived stem cells from the 5th passage were collected, and 1×106 cells were centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and the cells were washed with 1×PBS. The cell pellet, after removing the supernatant, was used for total RNA extraction using the TAKARA MiniBEST Universal RNA Extraction Kit (Cat. #9767). The extracted RNA was then used to synthesize cDNA using the PrimeScript™ 1st strand CDNA Synthesis Kit (Cat. 6110A). The gene expression levels were analyzed using real-time PCR with SYBR Green Premix Ex Taq II (Cat. #RR820S/A/B). The housekeeping gene GAPDH was used as a reference gene, and the expression of stem cell-related genes, such as Oct4, Sox2, and Nanog, was examined. Additionally, the expression of the known senescence-associated genes Foxo1 and Foxo3A was also analyzed. (Table 5)
As shown in
Through these data, it is confirmed that the cultivation of urine-derived stem cells with TM5-EXP and TM8 can enhance stem cell characteristics and cellular anti-aging properties. Particularly, TM8 cultivation significantly improves the expression of genes related to self-renewal and multipotency in urine-derived stem cells.
In this Example, cell proliferation rate or klotho gene analysis was conducted with various concentrations of lipid mixture (CDLC), T3, FGF23, Calcifediol, and PTH in the TM8 culture medium to explore their optimal concentrations (see
Specifically, CDLC was used to compensate for the decrease in cell proliferation rate caused by low serum usage, while T3 was used to facilitate the proliferation of urine-derived stem cells with characteristics of epithelial cells. In this example, evaluation was made of the improvement of cell proliferation rate in urine-derived stem cells in various concentration ranges of lipid mixture and T3 to determine their optimal concentrations.
Furthermore, FGF23, Calcifediol, and PTH that are added to the culture medium of the present disclosure are growth factors and hormones that interact through the endocrine system in the human kidney. The klotho proteins in the human body mediate these interactions. The inventors aimed to enhance the expression of klotho proteins in urine-derived stem cells by mimicking the endocrine system in the human body through the composition of the culture medium. In this Example, evaluation was made of the enhancement of klotho gene expression in urine-derived stem cells in various concentration ranges of FGF23, Calcifediol, and PTH to determine their optimal concentrations.
The results are depicted in
Moreover, the expression of klotho gene in urine-derived stem cells was compared by adding different concentrations of FGF23, Calcifediol, and PTH to the TM8 medium. As shown in
Additionally, in this Example, to explore the optimal concentrations while excluding the interactions among the substances, each substance was individually added to the TM8 basal medium (hereinafter referred to as proliferation or klotho gene TM8-Basal), and cell expression was analyzed and compared. The TM8 medium containing all substances at their optimal concentrations was used as the control group (
As shown in
Based on the data obtained in this Example, the inventors estimated that the combination of optimal concentrations of the aforementioned additives was the optimal composition of TM8. The performance of TM8 was compared and evaluated against the existing culture media in Table 3 in the previous examples.
In this Example, the klotho expression characteristics of the derived stem cells were compared and evaluated. Stem cells cultured up to the 5th passage using the media described in Table 3 were analyzed for klotho gene expression and klotho protein expression. Real-time polymerase chain reaction (PCR) analysis was performed for klotho gene expression, and western blotting was conducted using klotho primary antibody (Clone No. KM2076, TransGenic) for klotho protein expression.
As shown in
These results demonstrate that TM8 significantly enhances klotho expression in derived stem cells compared to Media 1 and Media 2. Moreover, TM8 showed a remarkable improvement in klotho protein expression compared to the previous TM5-EXP medium.
In this Example, the present inventors aimed to evaluate the efficacy of TM8, a medium developed by the present disclosure, in effectively inhibiting renal fibrosis. Initial kidney injury leads to tubular fibrosis, which is considered one of the key triggers for the progression of chronic kidney disease.
To create an in vitro model of tubular fibrosis, human proximal tubular epithelial cells (HK-2) were treated with a representative fibrosis-inducing factor, TGF-β1, at a concentration of 10 ng/ml for 3 days.
Concurrently, TM8-cultured derived stem cells (UDSCs) from the 5th passage were co-cultured with HK-2 cells for 3 days using a Transwell plate (Falcon, 6-well plate). As a control group, the representative mesenchymal stem cell line adipose-derived stem cells (ADSCs), which do not naturally express klotho, were used. Protein analysis was performed by western blotting to examine proteins involved in the downstream signaling pathway of TGF-β1.
As shown in
The inventors speculated that the inhibitory effect of TGF-β1 was attributed to the paracrine effect of Klotho protein secreted by urine-derived stem cells. To investigate this, the effects of urine-derived stem cells cultured in TM8 medium, which enhances klotho protein expression, were compared with the effects of UDSCs in which klotho protein expression was inhibited using siRNA. As shown in
Additionally, in this Example, evaluation was made of the ability of UDSCs cultured in TM8 medium to effectively inhibit podocyte apoptosis, which is responsible for the filtration function of the glomerulus. Podocytes play a central role in composing the glomerular basement membrane (GBM) and are known to be crucial for maintaining the glomerular filtration function. It has been observed that chronic kidney diseases and other renal injuries result in podocyte loss due to apoptosis, leading to significant damage to the glomerulus.
To create an in vitro model of podocyte apoptosis, the inventors treated CIHP-1, a human podocyte cell line, with Adriamycin (doxorubicin), a specific toxic drug for podocytes, at a concentration of 0.5 μM for 24 hours to induce fibrosis. Subsequently, UDSCs (urine-derived stem cells) from the 5th passage cultured in TM8 medium were co-cultured with CIHP-1 cells using a Transwell plate (Falcon, 6-well plate) for 3 days. Protein analysis was performed using Western blotting to analyze proteins such as p21, caspase-3, and p16, which are involved in the signaling pathway of p53, a key regulator of the cell cycle.
As shown in
These results demonstrate that UDSCs cultured in TM8 medium have enhanced klotho expression compared to conventional UDSCs, thereby proving their highly effective therapeutic potential in inhibiting renal fibrosis and podocyte apoptosis in kidney diseases such as chronic kidney disease.
In this Example, examination was made to determine whether the TM8-cultured UDSCs could migrate into the kidneys of mice with ischemia-reperfusion acute kidney injury, thereby participating in the regeneration process.
To induce ischemic reperfusion acute kidney injury, male BALB/c mice at 8 weeks of age were anesthetized, and the renal artery and vein were observed for 30 minutes. Immediately after inducing renal injury, PKH26-labeled UDSCs from the 4th passage of TM8 culture were administered through the tail vein at a concentration of 1×106 cells/head. After 24 hours of administration, the kidneys were harvested, and the migration of fluorescently labeled stem cells into the damaged kidneys was observed under a fluorescence microscope.
As shown in
In this Example, examination was made to validate the effectiveness of UDSCs derived from TM8 in promoting kidney tissue recovery and inhibiting fibrosis when administered into mice with ischemia-reperfusion acute kidney injury.
To induce ischemia-reperfusion acute kidney injury, mice were subjected to the injury procedure, and after 7 days, UDSCs cultured in TM8 were administered as a single dose at low, medium, and high concentrations (low dose, LS=4×104 cells/head; medium dose, MS=2×105 cells/head; high dose, HS=1×106 cells/head). After 7 days of cell administration, the mice from all experimental groups were sacrificed, and the effectiveness of UDSCs in mitigating kidney injury was evaluated.
As shown in
In addition, in this Example, the renal tissue of mice was collected and analyzed for the degree of kidney damage using HE staining.
The results, as shown in
Therefore, the administration of TM8-cultured urine-derived stem cells exhibited the ability to suppress kidney damage and promote tissue regeneration. The optimal efficacy was observed at the high dose (1×106/head), as it effectively inhibited tissue damage.
Having described a preferred embodiment of the present invention, it is to be understood that variants and modifications thereof falling within the spirit of the invention may become apparent to those skilled in this art, and the scope of this invention is to be determined by appended claims and their equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2021-0129299 | Sep 2021 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2022/005579 | 4/19/2022 | WO |
